Aferetica is mentioned in ‘FT1000‘, the ranking by Financial Times and Statista that collects the 1000 fastest-growing companies in Europe in 2022. Financial Times, together with Statista, brought together the business realities that achieved the highest growth rate (Cagr) in the past five years.
Together with Aferetica, 234 other Italian companies gained a place, giving to the Made in Italy the first position in the ranking. Germany follows with 194 and the United Kingdom with 155.
Since its birth in 2014, Aferetica has been committed to the development of new medical devices by applying apheresis as a therapy for the most varied clinical medical areas. It has developed systems including PerLife®, for the ex-vivo perfusion and reconditioning of abdominal organs. Moreover, the collaboration with international partners such as the US company CytoSorbents has resulted in the development of always new applications of blood purification in adverse clinical conditions.
Continuing to grow, doing research and innovation, for a real evolution of care, is the main purpose of Aferetica, which celebrates today’s goal with great satisfaction.
